Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale

Stroke

Volumn 38, Issue 7, 2007, Pages 2070-2073

  Botto, Nicoletta ^a   Spadoni, Isabella ^a   Giusti, Sandra ^a   Ait Ali, Lamia ^a   Sicari, Rosa ^b   Andreassi, Maria Grazia ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Genetics; Patent foramen ovale; Stroke care; Vein thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; ALLELE; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CHI SQUARE TEST; CONTROL GROUP; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RISK; GENOTYPE; GROUPS BY AGE; HEART ATRIUM SEPTUM DEFECT; HETEROZYGOTE; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ADULT; CARDIAC SURGICAL PROCEDURES; CEREBROVASCULAR ACCIDENT; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM;

EID: 34347347221     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.480863     Document Type: Article

References (22)

1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
2. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148-1152.
3. Wu LA, Malouf JF, Dearani JA, Hagler DJ, Reeder GS, Petty GW, Khandheria BK. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med. 2004;164:950-956.
4. Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, Gray W, Nakamura M, Mooney M, Poulose A, Schwartz RS. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46:1768-1776.
5. Ranoux D, Cohen A, Cabanes L, Amarenco P, Bousser MG, Mas JL. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke. 1993;24:31-34.
6. Schneider B, Hanrath P, Vogel P, Meinertz T. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J Am Coll Cardiol. 1990;16:1000-1009.
7. Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke. 2000;31:398-403.
8. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095-1108.
9. Aznar J, Mira Y, Vaya A, Corella D, Ferrando F, Villa P, Estelles A. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91:1031-1034.
10. Lalouschek W, Schillinger M, Hsieh K, Endler G, Tentschert S, Lang W, Cheng S, Mannhalter C. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005;36:1405-1409.
11. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, Akkawi NM, Albertini A, Assanelli D, Vignolo LA, Padovani A. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34:28-33.
12. Lichy C, Reuner KH, Buggle F, Litfin F, Rickmann H, Kunze A, Brandt T, Grau A. Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia. Cerebrovasc Dis. 2003;16:83-87.
13. Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis. 2003;14:261-268.
14. Stollberger C, Finsterer J. Search for coagulopathy does not obviate search for venous thrombosis in suspected paradoxical embolism. Stroke. 2003;34:e146-e147.
15. Federici C, Gianetti J, Andreassi MG. Genomic medicine and thrombotic risk: who, when, how and why. Int J Cardiol. 2006;106:3-9.
16. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-465.
17. Chant H, McCollum C. Stroke in young adult: the role of paradoxical embolism. Thromb Haemost. 2001;85:22-29.
18. Mas JL. Patent foramen ovale, atrial septal aneurysm and ischemic stroke in young adults. Eur Heart J. 1994;15:446-449.
19. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562-3565.
20. Sastry S, Riding G, Morris J, Taberner D, Cherry N, Heagerty A, McCollum C. Young Adult Myocardial Infarction and Ischemic Stroke: the role of paradoxical embolism and thrombophilia (The YAMIS Study). J Am Coll Cardiol. 2006;48:686-691.
21. Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, Mattle HP, Meier B. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-758.
22. Giardini A, Donti A, Formigari R, Bronzetti G, Prandstraller D, Bonvicini M, Palareti G, Guidetti D, Gaddi O, Picchio FM. Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol. 2004;94:1012-1016.